{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:17:02Z","timestamp":1777969022470,"version":"3.51.4"},"reference-count":34,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15531","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:52:52Z","timestamp":1773751972000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Administration of tirabrutinib suspension in a patient with primary central nervous system lymphoma: A case report"],"prefix":"10.3892","volume":"31","author":[{"given":"Takeo","family":"Yasu","sequence":"first","affiliation":[{"name":"Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo 204\u20118588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo 204\u20118588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Gando","sequence":"additional","affiliation":[{"name":"Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo 204\u20118588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Bokutoh Hospital\u2011Meiji Pharmaceutical University Joint Research Center, Tokyo 130\u20118575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"key20260505102801_b1-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"129531","DOI":"10.1016\/j.bbagen.2020.129531","article-title":"Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on- and off-target inhibition","volume":"1864","author":"Liclican","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"key20260505102801_b2-ol-31-5-15531","first-page":"46","article-title":"Case-based review: Primary central nervous system lymphoma","volume":"4","author":"Korfel","year":"2017","journal-title":"Neurooncol Pract"},{"key":"key20260505102801_b3-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3892\/ol.2023.13994","article-title":"Unusual localization and clinical presentation of primary central nervous system extranodal marginal zone B-cell lymphoma: A case report","volume":"26","author":"Fiorentino","year":"2023","journal-title":"Oncol Lett"},{"key":"key20260505102801_b4-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3892\/ol.2025.15179","article-title":"Morphological, immunophenotypic and neuroradiological characteristics of primitive B-large cell diffuse lymphoma of the central nervous system: A retrospective cohort analysis","volume":"30","author":"Rizzuto","year":"2025","journal-title":"Oncol Lett"},{"key":"key20260505102801_b5-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN guidelines\u00ae insights: Central nervous system cancers, version 2.2022","volume":"21","author":"Horbinski","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260505102801_b6-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/10428194.2024.2333985","article-title":"Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): Current progress and latest advances","volume":"65","author":"Schaff","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"key20260505102801_b7-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"key20260505102801_b8-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2147\/PPA.S253663","article-title":"Threshold size of medical tablets and capsules: Based on information collected by Japanese medical wholesaler","volume":"14","author":"Kabeya","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"key20260505102801_b9-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13691-021-00491-1","article-title":"Experience with nasogastric tube administration of tirabrutinib in the treatment of an elderly patient with primary central nervous system lymphoma","volume":"10","author":"Yoshioka","year":"2021","journal-title":"Int Cancer Conf J"},{"key":"key20260505102801_b10-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.21873\/anticanres.15917","article-title":"Experience with tirabrutinib in the treatment of primary central nervous system lymphoma that is difficult to treat with standard treatment","volume":"42","author":"Yoshioka","year":"2022","journal-title":"Anticancer Res"},{"key":"key20260505102801_b11-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"key":"key20260505102801_b12-ol-31-5-15531","article-title":"Guidance for Industry: Bioanalytical Method Validation","author":"National Library of Medicine","year":"2018"},{"key":"key20260505102801_b13-ol-31-5-15531","first-page":"1508","article-title":"Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib","volume":"61","author":"Okahashi","year":"2020","journal-title":"Rinsho Ketsueki"},{"key":"key20260505102801_b14-ol-31-5-15531","first-page":"5761627","article-title":"Ibrutinib treatment through nasogastric tube in a comatose patient with central nervous system localization of mantle cell lymphoma","volume":"2018","author":"Alsuliman","year":"2018","journal-title":"Case Rep Hematol"},{"key":"key20260505102801_b15-ol-31-5-15531","first-page":"6831237","article-title":"Lenvatinib administered via nasogastric tube in poorly differentiated thyroid cancer","volume":"2019","author":"Molinaro","year":"2019","journal-title":"Case Rep Endocrinol"},{"key":"key20260505102801_b16-ol-31-5-15531","first-page":"20","article-title":"Nasogastric administration of lenvatinib solution in a mechanically ventilated patient with rapidly growing anaplastic thyroid cancer","volume":"2020","author":"Kawano","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"key20260505102801_b17-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.21037\/apm-21-940","article-title":"Nasogastric administration of osimertinib suspension for an epidermal growth factor receptor-mutated lung cancer causing an esophageal stricture: Case report","volume":"11","author":"Tani","year":"2022","journal-title":"Ann Palliat Med"},{"key":"key20260505102801_b18-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"e00241","DOI":"10.1002\/rcr2.241","article-title":"Osimertinib administration via nasogastric tube in an EGFR-T790M-positive patient with leptomeningeal metastases","volume":"5","author":"Takeda","year":"2017","journal-title":"Respirol Case Rep"},{"key":"key20260505102801_b19-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"bcr2013202705","DOI":"10.1136\/bcr-2013-202705","article-title":"Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia","volume":"2014","author":"Suzumura","year":"2014","journal-title":"BMJ Case Rep"},{"key":"key20260505102801_b20-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1177\/1078155218793197","article-title":"Response to alectinib oil-based suspension in anaplastic lymphoma kinase-positive non-small cell lung cancer in a patient unable to swallow: A case report","volume":"25","author":"Bejarano Varas","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"key20260505102801_b21-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ccr3.973","article-title":"Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance status","volume":"5","author":"Kanai","year":"2017","journal-title":"Clin Case Rep"},{"key":"key20260505102801_b22-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"e27611","DOI":"10.1097\/MD.0000000000027611","article-title":"Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report","volume":"100","author":"Thomas","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"key20260505102801_b23-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.lungcan.2014.07.010","article-title":"Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma","volume":"86","author":"Bosch-Barrera","year":"2014","journal-title":"Lung Cancer"},{"key":"key20260505102801_b24-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"e00796","DOI":"10.1002\/rcr2.796","article-title":"Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: Carcinomatous meningitis, poor performance status, and dysphagia-a case report","volume":"9","author":"Sasaki","year":"2021","journal-title":"Respirol Case Rep"},{"key":"key20260505102801_b25-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3892\/ol.2023.14113","article-title":"Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase-positive non-small cell lung cancer: A case report","volume":"26","author":"Wang","year":"2023","journal-title":"Oncol Lett"},{"key":"key20260505102801_b26-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/j.cllc.2023.12.013","article-title":"To crush or not to crush: Administering dabrafenib and trametinib through a nasogastric tube in a critically ill patient with nonsmall cell lung cancer-a case report and review of literature of targeted therapies given through enteral feeding tubes","volume":"25","author":"Jang","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"key20260505102801_b27-ol-31-5-15531","first-page":"1769","article-title":"Chronic myeloid leukemia complicated with cerebellar hemorrhage and acute hydrocephalus successfully treated with imatinib and intensive supportive care","volume":"51","author":"Muta","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"key20260505102801_b28-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/cas.13983","article-title":"Phase I study of tirabrutinib (ONO-4059\/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan","volume":"110","author":"Munakata","year":"2019","journal-title":"Cancer Sci"},{"key":"key20260505102801_b29-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"e2460780","DOI":"10.1001\/jamanetworkopen.2024.60780","article-title":"Use of feeding tubes among hospitalized older adults with dementia","volume":"8","author":"Hartford","year":"2025","journal-title":"JAMA Netw Open"},{"key":"key20260505102801_b30-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.clinthera.2004.10.011","article-title":"Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: Results of a randomized, open-label, three-period crossover study in healthy volunteers","volume":"26","author":"Cantarini","year":"2004","journal-title":"Clin Ther"},{"key":"key20260505102801_b31-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/cts.13515","article-title":"Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling","volume":"16","author":"Liu","year":"2023","journal-title":"Clin Transl Sci"},{"key":"key20260505102801_b32-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s10637-015-0245-3","article-title":"Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT)","volume":"33","author":"Chiu","year":"2015","journal-title":"Invest New Drugs"},{"key":"key20260505102801_b33-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/cncr.25769","article-title":"Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma","volume":"117","author":"Brooks","year":"2011","journal-title":"Cancer"},{"key":"key20260505102801_b34-ol-31-5-15531","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s10637-011-9725-2","article-title":"A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors","volume":"30","author":"Heath","year":"2012","journal-title":"Invest New Drugs"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:28:11Z","timestamp":1777966091000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15531","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}